DYN Q2 2017 Earnings — Dyne Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

DYNDyne Therapeutics, Inc.

$3B

Q2 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$181M+9.0% YoY

Gross Profit

-$500M-276.2% margin

Operating Income

$20M11.0% margin

Net Income

-$296M-163.5% margin

EPS (Diluted)

$-1.83

QoQ Revenue Growth

+3.4%

Cash Flow

Operating Cash Flow

$81M

Free Cash Flow

$112M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$12.8B

Total Liabilities

$10.6B

Stockholders' Equity

$2.1B

Cash & Equivalents

$447M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$181M	$166M	+9.0%
Gross Profit	-$500M	-$327M	-52.9%
Operating Income	$20M	-$552M	+103.6%
Net Income	-$296M	-$803M	+63.1%